Is the price fair?
What EW's price assumes
Edwards Lifesciences trades at 52.2× earnings against 33.4× for the median Medical Devices name, more expensive than its own group.
52.2
Trailing P/E · Medical Devices median 33.4 · 1.56× the median: the market pays up for this one
- Price / sales
- 7.38
Price / sales · as of 2026-Q1
- Free cash flow yield
- 2.9%
Free cash flow yield · Medical Devices median 4.0%
- Growth the price implies
- +13%
Growth the price implies · The price pays for +13% free cash flow growth a year for a decade; the business has delivered +27% a year over the last three.
Details›
- Price / book2026-Q1
- 4.50
- EV / EBIT2026-Q1
- 33.1
- EV / sales2026-Q1
- 7.08
- Healthcare median P/E362 names
- 31.5
- Medical Devices median P/E39 names
- 33.4
- Free cash flow, trailing twelve months
- $1.43B
- Market capitalisation
- $50.3B
- 3-year revenue growth
- +15%
- 3-year free cash flow growth
- +27%
| Method | Per share |
|---|---|
| Its own P/E history, lower quartile | $29.09 |
| Its own P/E history, median | $59.83 |
| Its own P/E history, upper quartile | $77.64 |
| 52-week range | $72.65 – $93.67 |
| Today | $90.77 |
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Medical Devices
Ranks #18 of 35 by Smart Score